利拉鲁肽通过调控表面活性蛋白表达与分泌减轻肺炎诱导脓毒症的急性肺损伤与死亡率
本研究在野生型FVB/NJ小鼠(n=114)经气管内注射铜绿假单胞菌Xen5(4×10^4 CFU/只)或等体积(50 μL)生理盐水构建肺炎诱导脓毒症模型,感染后30分钟皮下注射利拉鲁肽2 mg/kg,24小时处死分析肺组织与支气管肺泡灌洗液(BALF),另设实验用活体成像系统监测感染后48小时内细菌动态生长与动物死亡率。结果显示利拉鲁肽改善生存(P<0.05)、降低体内细菌负荷、降低肺损伤评分(P<0.01),并减少肺内炎症细胞(P<0.01)与促炎细胞因子TNF-α、IL-6(P<0.01),同时显著增加肺表面活性蛋白SP-A、SP-B表达/分泌(P<0.01)及磷脂分泌(P<0.01)。原代肺泡II型细胞经利拉鲁肽预处理后,LPS暴露下SP-A与SP-B表达改善(P<0.01)。结论认为利拉鲁肽减轻肺炎诱导脓毒症的死亡率与肺部炎症/损伤,其增加表面活性物质表达/分泌与抗炎效应可能是GLP-1激动剂增强宿主防御、维持肺泡呼吸功能的潜在机制。
要点
- 小鼠肺炎诱导脓毒症模型中,感染后30分钟皮下注射利拉鲁肽2 mg/kg,24小时肺损伤评分降低(P<0.01)、肺内炎症细胞减少(P<0.01)。
- 同模型48小时内监测显示利拉鲁肽改善生存(P<0.05)并降低体内细菌负荷。
- 利拉鲁肽降低肺内促炎细胞因子TNF-α与IL-6水平(P<0.01),并增加肺表面活性蛋白SP-A、SP-B表达/分泌(P<0.01)及磷脂分泌(P<0.01)。
- 原代肺泡II型细胞经利拉鲁肽预处理后,LPS暴露下SP-A与SP-B表达改善(P<0.01),支持表面活性物质调控机制。
适用人群与场景
- 野生型FVB/NJ小鼠(n=114),经气管内注射铜绿假单胞菌Xen5(4×10^4 CFU/只)构建肺炎诱导脓毒症模型;对照为等体积(50 μL)生理盐水气管内注射。
处置流程与药物剂量
- 小鼠感染后30分钟皮下注射利拉鲁肽2 mg/kg;感染后24小时处死分析肺组织与BALF,另设实验在感染后48小时内用活体成像系统监测细菌动态生长与动物死亡率。
研究设计与关键结果
- 研究类型:动物实验(小鼠肺炎诱导脓毒症模型);样本量n=114只野生型FVB/NJ小鼠;干预为感染后30分钟皮下注射利拉鲁肽2 mg/kg,对照为感染后不给利拉鲁肽。
- 主要终点:利拉鲁肽改善生存(P<0.05)、降低体内细菌负荷、降低肺损伤评分(P<0.01)。
- 关键次要终点:利拉鲁肽组肺内炎症细胞减少(P<0.01),促炎细胞因子TNF-α与IL-6降低(P<0.01);肺表面活性蛋白SP-A、SP-B表达/分泌增加(P<0.01),磷脂分泌增加(P<0.01)。
- 机制实验:原代肺泡II型细胞经利拉鲁肽预处理后,LPS暴露下SP-A与SP-B表达改善(P<0.01)。
证据类型、等级与局限
- 证据类型:动物实验(小鼠模型)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 原文结论认为利拉鲁肽减轻肺炎诱导脓毒症的死亡率与肺部炎症/损伤,其增加表面活性物质表达/分泌与抗炎效应可能是GLP-1激动剂增强宿主防御、维持肺泡呼吸功能的潜在机制;原文未据此给出临床推荐。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Glucagon-like peptide 1 (GLP-1) analogs are used to treat type 2 diabetes, and they can regulate insulin secretion, energy homeostasis, inflammation, and immune cell function. This study sought to determine whether the GLP-1 analog liraglutide exerts a beneficial action in an acute lung injury model of pneumonia-induced sepsis. Methods: Wild-type FVB/NJ mice (n = 114) were infected by intratracheal injection with Pseudomonas aeruginosa Xen5 (4 × 10 4 CFU/mouse) or an equal volume (50 μL) of saline (control) with or without a subcutaneous injection of liraglutide (2 mg/kg, 30 min after infection). Mice were killed 24 h after infection. Lung tissues and BALF were analyzed. In separate experiments, the dynamic growth of bacteria and animal mortality was monitored using in vivo imaging system within 48 h after infection. In addition, primary lung alveolar type II cells isolated from mice were used to study the mechanism of liraglutide action. Result: Liraglutide improved survival ( P < 0.05), decreased bacterial loads in vivo , and reduced lung injury scores ( P < 0.01) in septic mice. Liraglutide-treated mice showed decreased levels of inflammatory cells ( P < 0.01) and proinflammatory cytokines (TNF-α and IL-6) ( P < 0.01) in the lung compared with septic controls. Liraglutide significantly increased pulmonary surfactant proteins (SP-A and SP-B) expression/secretion ( P < 0.01) and phospholipid secretion ( P < 0.01) in vivo . Primary alveolar type II cells pretreated with liraglutide improved SP-A and SP-B expression after LPS exposure ( P < 0.01). Conclusion: Liraglutide attenuates mortality and lung inflammation/injury in pneumonia-induced sepsis. The increased surfactant expression/secretion and anti-inflammatory effects of liraglutide represent potential mechanisms by GLP-1 agonists potentiate host defense and maintain alveolar respiratory function in acute lung injury.
参考来源
- Guo J, Chen X, Wang C, et al. LIRAGLUTIDE ALLEVIATES ACUTE LUNG INJURY AND MORTALITY IN PNEUMONIA-INDUCED SEPSIS THROUGH REGULATING SURFACTANT PROTEIN EXPRESSION AND SECRETION. Shock. 2023. PMID: 38150354. doi:10.1097/SHK.0000000000002285
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。